Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ganciclovir + infliximab + mesalamine + rivaroxaban
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Rectal, Ophthalmic
01
Overview
This is a combination of four separate medications with different therapeutic purposes. Ganciclovir is an antiviral medication used to treat cytomegalovirus (CMV) infections. Infliximab is a monoclonal antibody that blocks tumor necrosis factor alpha (TNF-α), used for inflammatory conditions such as Crohn's disease and ulcerative colitis. Mesalamine is an anti-inflammatory drug used primarily for inflammatory bowel diseases. Rivaroxaban is an anticoagulant medication.
02
Targets
ALOX5 (Arachidonate 5-lipoxygenase)F10 (Factor Xa)CMV DNA polymerase (Human cytomegalovirus DNA polymerase)PPARG (Peroxisome proliferator-activated receptor gamma)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TNFA (Tumor necrosis factor alpha (soluble))DNA polymerase family
Beyond the preview
Go deeper on ganciclovir + infliximab + mesalamine + rivaroxaban.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ganciclovir + infliximab + mesalamine + rivaroxaban.